VCL::ROS1 : A Novel ROS1 Oncogenic Fusion Detected on Next Generation Sequencing.

Autor:	Mehta, Anurag, Diwan, Himanshi, Nathany, Shrinidhi, Batra, Ullas, Gupta, Manoj, Panigrahi, Manoj Kumar, Kumar, Dushyant, Mattoo, Sakshi, Singh, Aayushi
Předmět:	PROTEIN-tyrosine kinase inhibitors IMMUNOHISTOCHEMISTRY CELL lines FLUORESCENCE in situ hybridization LUNG cancer SEQUENCE analysis
Zdroj:	Clinical Pathology; 8/12/2024, p1-4, 4p
Abstrakt:	Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with ROS1 gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40 fusion partners documented in the existing literature. Our report highlights a novel fusion partner of ROS1 that has demonstrated a conclusive response to the current standard of treatment. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.